You searched for Switzerland - Page 32 of 39

AC Immune Genentech crenezumab phase III

News and Trends 28 Feb 2017

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

The Swiss biotech AC Immune announced that its partner Genentech (Roche) will start a second phase III clinical trial for its Alzheimer’s therapy crenezumab. In 2006 AC Immune partnered up…

February 28, 2017 - 3 minutesmins - By Melanie De Almeida

In Depth 23 Aug 2022

Company’s 3D microchip gives mechanistic insights into human brain

A microchip that allows scientists to study the complexity of 3D cellular networks at unrivaled scale and precision has been added to 3Brain AG’s brain-on-chip portfolio. In collaboration with Swiss…

August 23, 2022 - 5 minutesmins - By Liza Laws

News and Trends 10 Apr 2017

The Biggest European Medtech Exit of 2017 Just Happened

The medtech company Symetis, specialized in heart valve replacements, today announced its acquisition by Boston Scientific in a hefty €411M ($435M) deal. Symetis is a Swiss medtech company and one…

April 10, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 12 Apr 2017

Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics

Swiss Polyphor has closed a €37M (CHF40M) private funding round to finance the development of its most advanced candidate tackling antibiotic resistances. Polyphor is a clinical stage pharma developing a…

April 12, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 15 Jun 2017

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Novartis has announced positive post-marketing results for its blockbuster Cosentyx, with which the pharma wants to compete with the best-selling drug. At the 2017 Annual European Congress of Rheumatology, currently…

June 15, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 6 Nov 2017

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines

NousCom is developing semi-personalized medicine that convinced investors like Abingworth to go in big for its off-the-shelf neoantigen vaccines. Based in Basel and run by a team of serial entrepreneurs…

November 6, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 26 Sep 2016

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

It’s not the $700M headlines imply, but AC Immune is winding up to make a splashy IPO of €52.5M to establish itself in the Alzheimer’s Disease space. You might have…

September 26, 2016 - 2 minutesmins - By Evelyn Warner

crispr therapeutics gene editing labiotech refresh philip hemme biotech roger novak

News and Trends 1 Jun 2016

CRISPR Thx’ Founder: “We have over $250M in the bank”

So begins our series of videos documenting our biotech conference premier – Labiotech Refresh. Here Philip spoke with Rodger Novak, the CEO and founder of CRISPR Therapeutics, which is leading…

June 1, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 12 May 2023

Cell and gene therapy company NewBiologix exits stealth with $50M

NewBiologix SA has emerged from stealth as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell…

May 12, 2023 - 3 minutesmins - By Jim Cornall

philipp hemme labiotech conference novartis sachs biotech markus goebel

News and Trends 29 Mar 2016

Interviewing the Managing Director of the $750M Venture Fund of Novartis

This is last interview you will see from SACHS in Zurich. I met with Markus Goebel, the managing director of the Novartis Venture Fund. He almost played at home as…

March 29, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 7 Dec 2017

Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival

A new first-line combination therapy for advanced non-squamous non-small-cell lung cancer improved progression-free survival during a Phase III trial. Scientists based at the Lung Clinic Grosshansdorf, Hamburg, and Centre Hospitalier…

December 7, 2017 - 3 minutesmins - By Alex Dale

News and Trends 24 Mar 2017

Novartis puts the Development of two Anti-Aging Drugs in American Hands

PureTech will take on the development of two mTORC1 inhibitors from Novartis aimed at stopping the decline of the immune system associated with age. Novartis is building up the portfolio…

March 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: Switzerland

Hopes are up: A Second Phase III Trial for Alzheimer’s Disease

Company’s 3D microchip gives mechanistic insights into human brain

The Biggest European Medtech Exit of 2017 Just Happened

Swiss Pharma Clears €37M Funding to Develop a New Class of Antibiotics

Novartis Announces New Data for its Psoriasis Blockbuster Cosentyx

Swiss Biotech Pulls Major Investors into €42M Series B for Cancer Vaccines

UPDATE: AC Immune rakes in €52.5M IPO for assault on Alzheimers

CRISPR Thx’ Founder: “We have over $250M in the bank”

Cell and gene therapy company NewBiologix exits stealth with $50M

Interviewing the Managing Director of the $750M Venture Fund of Novartis

Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival

Novartis puts the Development of two Anti-Aging Drugs in American Hands

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!